Literature DB >> 12471610

Current status of the molecular genetics of human prostatic adenocarcinomas.

Dev Karan1, Ming-Fong Lin, Sonny L Johansson, Surinder K Batra.   

Abstract

Molecular genetic mechanisms involved in the progression of prostate cancer are not well understood due to extensive tumor heterogeneity and lack of suitable models. New methods such as fluorescence in-situ hybridization (FISH), comparative genomic hybridization (CGH) and microsatellite analysis have documented losses or gains on various chromosomes. Altered chromosomal regions have been associated with the activation of oncogenes and the inactivation of tumor suppressor genes or defects in mismatch repair (MMR) genes. It is suggested that increased genomic instability is associated with decreased androgen-responsive and progressive behavior of human prostate tumors, but it remains unclear whether this genomic instability is causing the progression of cancer or is the consequence of cancer. Extended studies on hereditary prostate cancer have identified 7 prostate cancer susceptibility loci on several chromosomes, but no specific gene has been confined for a large proportion of susceptibility. In this review we summarize the ongoing molecular genetic events associated with the sporadic and hereditary prostate cancer development and progression. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12471610     DOI: 10.1002/ijc.10813

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

Review 1.  Krüppel cripples prostate cancer: KLF6 progress and prospects.

Authors:  Goutham Narla; Scott L Friedman; John A Martignetti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

2.  The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Authors:  L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-23       Impact factor: 5.554

3.  The emerging role of matrix metalloproteases of the ADAM family in male germ cell apoptosis.

Authors:  Ricardo D Moreno; Paulina Urriola-Muñoz; Raúl Lagos-Cabré
Journal:  Spermatogenesis       Date:  2011-07-01

4.  Analysis of differentially expressed genes, clinical value and biological pathways in prostate cancer.

Authors:  Zhaohui He; Fucai Tang; Zechao Lu; Yucong Huang; Hanqi Lei; Zhibiao Li; Guohua Zeng
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

5.  Long intragenic non-coding RNA lincRNA-p21 suppresses development of human prostate cancer.

Authors:  Xiaohai Wang; Yuan Ruan; Xingjie Wang; Wei Zhao; Qi Jiang; Chenyi Jiang; Yuyang Zhao; Yongzhi Xu; Feng Sun; Yiping Zhu; Shujie Xia; Dongliang Xu
Journal:  Cell Prolif       Date:  2016-12-14       Impact factor: 6.831

Review 6.  Molecular basis for prostate cancer racial disparities.

Authors:  Santosh K Singh; James W Lillard; Rajesh Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01

7.  Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates.

Authors:  André Fujita; Luciana Rodrigues Gomes; João Ricardo Sato; Rui Yamaguchi; Carlos Eduardo Thomaz; Mari Cleide Sogayar; Satoru Miyano
Journal:  BMC Syst Biol       Date:  2008-12-05

8.  U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.

Authors:  Ekwere T Ifon; Alan L Y Pang; Warren Johnson; Kathleen Cashman; Sharon Zimmerman; Sumitra Muralidhar; Wai-Yee Chan; John Casey; Leonard Jason Rosenthal
Journal:  Cancer Cell Int       Date:  2005-06-22       Impact factor: 5.722

9.  Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers.

Authors:  Magdalena Bryś; Monika Migdalska-Sęk; Dorota Pastuszak-Lewandoska; Ewa Forma; Karolina Czarnecka; Daria Domańska; Ewa Nawrot; Jacek Wilkosz; Waldemar Różański; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2013-01-04       Impact factor: 3.064

10.  Is PTEN loss associated with clinical outcome measures in human prostate cancer?

Authors:  P McCall; C J Witton; S Grimsley; K V Nielsen; J Edwards
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.